Trials / Conditions / Acute Leukemia of Ambiguous Lineage

Acute Leukemia of Ambiguous Lineage

21 registered clinical trials studyying Acute Leukemia of Ambiguous Lineage — 13 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukem NCT07094750	Fred Hutchinson Cancer Center	N/A
Withdrawn	A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participan NCT05521087	Janssen Research & Development, LLC	Phase 1
Recruiting	Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and NCT07046078	Fred Hutchinson Cancer Center	Phase 2
Recruiting	Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to t NCT06317662	National Cancer Institute (NCI)	Phase 2
Recruiting	Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant NCT06575296	City of Hope Medical Center	Phase 1
Recruiting	Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hig NCT06013423	Fred Hutchinson Cancer Center	Phase 2
Recruiting	Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583	Imperial College London	Phase 2
Recruiting	Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relap NCT06177067	St. Jude Children's Research Hospital	Phase 1
Recruiting	Venetoclax Combined With Azactidine in the Treatment of ALAL NCT05901974	Sheng-Li Xue, MD	Phase 2
Recruiting	Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664	Andrew E. Place, MD	Phase 1
Recruiting	Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous L NCT04440267	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Recruiting	A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation NCT04065399	Syndax Pharmaceuticals	Phase 1 / Phase 2
Recruiting	First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia NCT04067336	Kura Oncology, Inc.	Phase 1 / Phase 2
Recruiting	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Bloo NCT03779854	Fred Hutchinson Cancer Center	Phase 2
Completed	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene NCT02828358	National Cancer Institute (NCI)	Phase 2
Completed	Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With New NCT03012672	University of Washington	Phase 2
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985	Fred Hutchinson Cancer Center	Phase 2
Completed	Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Di NCT02135874	M.D. Anderson Cancer Center	Phase 2
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in NCT01858740	Fred Hutchinson Cancer Center	Phase 2
Terminated	Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refr NCT01701323	Nohla Therapeutics, Inc.	Phase 1
Completed	POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients NCT01319864	Seattle Children's Hospital	Phase 1